U.K. Bill For those worried about Cohodes B.S. about the new U.K. legislation see below - have a good weekend guys, we'll see if Thompson's travels bring a NR on Monday.
From the Q2 CC:
David Martin
Hi, thanks for taking my questions. First one, I’m wondering if any of your drugs in North America were aware of the CBS situation. But have any other major formularies excluded any of your drugs? And in the UK, have you been formally approached by the Department of Health on pricing issues?
Mark Thompson
Okay, I’ll do the UK one first, because that’s straightforward. No, we haven’t.
David Martin
Are you in anyway changing your strategy around product pricing in the UK, because of the political climate?
Mark Thompson
No, no. As I said before, actually going forward, the main driver of growth in the UK and actually indeed the International business is product launch. Interestingly those – the products that we’re launching, the 60 of them that are due to launch by the end of 2018, the majority of those – big majority of those op cost saving medicines for NHS, which was always part of our strategy, is always part of our strategy. So we’re not having to adjust anything.